Janssen Biotech Inc.
800 Ridgeview Drive
150 articles with Janssen Biotech Inc.
Nuevolution today announced that Janssen Biotech has exercised its option to license one of the research programs under the multi-target collaboration entered between the parties in October 2015 - a collaboration that was expanded further in April 2016 and March 2017.
Alligator Bioscience to Receive USD 6 Million Milestone Payment From Janssen Coupled to the Decision to Initiate Combination Trial With ADC-1013
This is the first out of a number of pre-defined milestones, related to the start of combination or phase II studies as part of the ADC-1013 clinical program.
12/22/2017Janssen Biotech announced today that it has entered into a worldwide collaboration and license agreement with Legend Biotech USA and Legend to develop, manufacture and commercialize a CAR T-cell drug candidate, LCAR-B38M.
U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer
Janssen Biotech today announced that the FDA has granted Priority Review designation for the NDA for apalutamide, an investigational, next-generation oral androgen receptor inhibitor for the treatment of men with non-metastatic CRPC.
Today, Janssen Biotech announced it had exercised its option to enter into a collaboration deal with Idorsia to jointly develop and market aprocitentan and any derivative compounds.
Janssen Submits Application to U.S. FDA to Expand Indication for DARZALEX (daratumumab) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma who are Transplant Ineligible
Janssen Biotech today announced that it has submitted a supplemental sBLA to the FDA for DARZALEX (daratumumab).
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple Myeloma
In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab.
The milestone was triggered by confirmation by Janssen that sales of Darzalex reached $1 billion in a calendar year.
There's nothing like a billion-plus dollar deal to make investors happy on a Monday.
Janssen Receives Two FDA Approvals for SIMPONI ARIA (golimumab) for the Treatment of Adults With Active Psoriatic Arthritis or Active Ankylosing Spondylitis
Janssen Biotech announced today that the FDA has approved SIMPONI ARIA (golimumab), the only fully-human anti-TNF-alpha therapy administered via a 30-minute infusion, for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis (AS).
Janssen Announces FDA Approval Of STELARA (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
Janssen Biotech announced today that the FDA has approved an expanded indication for STELARA (ustekinumab) for the treatment of adolescents (12 years of age or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Janssen Biotech Submits New Drug Application To U.S. FDA For Apalutamide (ARN-509) To Treat Men With Non-Metastatic Castration-Resistant Prostate Cancer
MorphoSys AG Announces That Its Licensee Janssen Biotech Has Initiated Two Phase III Studies With Tremfyatm (Guselkumab) In Psoriatic Arthritis
Janssen Biotech Submits Supplemental New Drug Application To U.S. FDA For ZYTIGA (Abiraterone Acetate) To Treat Men With Earlier Stages Of Metastatic Prostate Cancer
Phenex Pharmaceuticals AG Announces Milestone Payment From Janssen Biotech For The Entry Of Rorgt Inhibitor Into Phase I
Adaptive Biotech Announces A Collaboration With Janssen Biotech To Use The clonoSEQ? Assay To Measure Minimal Residual Disease In Ongoing And Future DARZALEX? Multiple Myeloma Trials
Adaptive Biotech Announces A Collaboration With Janssen Biotech To Use The Clonoseq Assay To Measure Minimal Residual Disease In Ongoing And Future DARZALEX Multiple Myeloma Trials
Janssen Biotech Release: DARZALEX (daratumumab) Approved By The U.S. FDA In Combination With Pomalidomide And Dexamethasone For Patients With Multiple Myeloma Who Have Received At Least Two Prior Therapies
Pulmatrix Licenses Novel Drug Candidates From RespiVert Ltd., A Wholly Owned Subsidiary Of Janssen Biotech